DNDi IP Policy

DNDi is a non-profit R&D organization, founded in Geneva in 2003, that works with partners to develop new treatments for neglected diseases. Here is a link to the organization's pragmatic IP Policy, which may be of interest to those following discussions of IP, health innovation, and access to health technologies. DNDi is home to GARDP (the Global Antibiotic Research and Development Partnership), a joint WHO/DNDi initiative launched in 2016 that is focused on the development of new antibiotics for treating sepsis and STIs such as gonorrhoea. An important part of the work of DNDi, and of GARDP, is to ensure the broadest possible access to any products developed; this requires active engagement across the entire innovation value chain, including manufacture and distribution. 

July 2017